Cui X, Hou L, Yan B, Liu J, Zhang C, Sui P
J Clin Invest. 2025; 135(5).
PMID: 39836478
PMC: 11870739.
DOI: 10.1172/JCI182125.
Miyao K, Murata M, Nishida T, Ozawa Y, Uchida N, Fukuda T
Int J Hematol. 2024; 121(1):110-125.
PMID: 39543007
DOI: 10.1007/s12185-024-03871-4.
Zhang C, Hao T, Bortoluzzi A, Chen M, Wu X, Wang J
Oncogene. 2024; 44(2):64-78.
PMID: 39487323
PMC: 11706783.
DOI: 10.1038/s41388-024-03197-9.
Mian S, Ariza-McNaughton L, Anjos-Afonso F, Guring R, Jackson S, Kizilors A
Hemasphere. 2024; 8(5):e80.
PMID: 38774656
PMC: 11107397.
DOI: 10.1002/hem3.80.
Pacini C, Soares M, Lacerda J
Front Immunol. 2024; 15:1339318.
PMID: 38711496
PMC: 11070504.
DOI: 10.3389/fimmu.2024.1339318.
Determining the predictive impact of donor parity on the outcomes of human leukocyte antigen matched hematopoietic stem cell transplants: a retrospective, single-center study.
Azari M, Barkhordar M, Bahri T, Rad S, Kamranzadeh Fumani H, Mousavi S
Front Oncol. 2024; 14:1339605.
PMID: 38454927
PMC: 10918844.
DOI: 10.3389/fonc.2024.1339605.
Prediction model for EBV infection following HLA haploidentical matched hematopoietic stem cell transplantation.
Cao X, Fan Z, Chang Y, Xu L, Zhang X, Huang X
J Transl Med. 2024; 22(1):244.
PMID: 38448996
PMC: 10916301.
DOI: 10.1186/s12967-024-05042-9.
Impact of anti-thymocyte globulin on survival outcomes in female-to-male allogeneic hematopoietic stem cell transplantation.
Tamaki M, Akahoshi Y, Ashizawa M, Misaki Y, Koi S, Kim S
Sci Rep. 2023; 13(1):7166.
PMID: 37138004
PMC: 10156723.
DOI: 10.1038/s41598-023-34442-y.
Haploidentical vs matched unrelated donors for patients with ALL: donor age matters more than donor type.
Mehta R, Marin D, Alousi A, Kanakry C, Champlin R, Rezvani K
Blood Adv. 2023; 7(8):1594-1603.
PMID: 36630564
PMC: 10139863.
DOI: 10.1182/bloodadvances.2022009240.
Chronic graft-versus-host disease. Part I: Epidemiology, pathogenesis, and clinical manifestations.
Baumrin E, Loren A, Falk S, Mays J, Cowen E
J Am Acad Dermatol. 2022; 90(1):1-16.
PMID: 36572065
PMC: 10287844.
DOI: 10.1016/j.jaad.2022.12.024.
Low-Dose Anti-Thymocyte Globulin Plus Low-Dose Posttransplant Cyclophosphamide as an Effective Regimen for Prophylaxis of Graft Host Disease After Haploidentical Peripheral Blood Stem Cell Transplantation With Maternal/Collateral Related Donors.
Li T, He Q, Yang J, Cai Y, Huang C, Xu X
Cell Transplant. 2022; 31:9636897221139103.
PMID: 36433646
PMC: 9706219.
DOI: 10.1177/09636897221139103.
Age and allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia.
Yanada M, Yamasaki S, Konuma T, Mizuno S, Uchida N, Onai D
Int J Hematol. 2022; 117(3):398-408.
PMID: 36335534
DOI: 10.1007/s12185-022-03486-7.
Natural Barcodes for Longitudinal Single Cell Tracking of Leukemic and Immune Cell Dynamics.
Penter L, Gohil S, Wu C
Front Immunol. 2022; 12:788891.
PMID: 35046946
PMC: 8761982.
DOI: 10.3389/fimmu.2021.788891.
Female Sex Is Associated with Improved Long-Term Survival Following Allogeneic Hematopoietic Stem Cell Transplantation.
Islam P, Tang H, Jin H, Cao F, Bohannon L, Ren Y
Transplant Cell Ther. 2021; 27(9):784.e1-784.e7.
PMID: 34146734
PMC: 8403653.
DOI: 10.1016/j.jtct.2021.06.012.
Prognostic effect of gender on outcome of treatment for adults with acute myeloid leukaemia.
Wiernik P, Sun Z, Cripe L, Rowe J, Fernandez H, Luger S
Br J Haematol. 2021; 194(2):309-318.
PMID: 34145576
PMC: 8532194.
DOI: 10.1111/bjh.17523.
Relationship of donor age and relationship to outcomes of haploidentical transplantation with posttransplant cyclophosphamide.
DeZern A, Franklin C, Tsai H, Imus P, Cooke K, Varadhan R
Blood Adv. 2021; 5(5):1360-1368.
PMID: 33661299
PMC: 7948266.
DOI: 10.1182/bloodadvances.2020003922.
Relapsed Chronic Lymphocytic Leukaemia with Concomitant Extensive Chronic Graft versus Host Disease after Allogeneic Haematopoietic Stem Cell Transplantation Successfully Treated with Oral Venetoclax.
Teoh C, Goh A
Case Rep Transplant. 2021; 2021:8831125.
PMID: 33552611
PMC: 7846410.
DOI: 10.1155/2021/8831125.
New Approaches for the Treatment of Chronic Graft-Versus-Host Disease: Current Status and Future Directions.
Saidu N, Bonini C, Dickinson A, Grce M, Inngjerdingen M, Koehl U
Front Immunol. 2020; 11:578314.
PMID: 33162993
PMC: 7583636.
DOI: 10.3389/fimmu.2020.578314.
Impact of donor age and kinship on clinical outcomes after T-cell-replete haploidentical transplantation with PT-Cy.
Mariotti J, Raiola A, Evangelista A, Carella A, Martino M, Patriarca F
Blood Adv. 2020; 4(16):3900-3912.
PMID: 32813875
PMC: 7448598.
DOI: 10.1182/bloodadvances.2020001620.
T-Cell Immunotherapies Targeting Histocompatibility and Tumor Antigens in Hematological Malignancies.
Janelle V, Rulleau C, Del Testa S, Carli C, Delisle J
Front Immunol. 2020; 11:276.
PMID: 32153583
PMC: 7046834.
DOI: 10.3389/fimmu.2020.00276.